NasdaqGS:ROIVBiotechs
Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum
Earnings and Clinical Data Put Roivant in Focus
Roivant Sciences (ROIV) has moved into the spotlight after reporting Phase 2b results for IMVT-1402 in difficult-to-treat rheumatoid arthritis, alongside recent fourth quarter earnings and a new shelf registration filing.
See our latest analysis for Roivant Sciences.
At a share price of US$29.88, Roivant has seen a 36.25% year to date share price return and a very large 1 year total shareholder return, suggesting momentum has built around the...